Millipede Medical

Millipede Medical – the system developer of Iris with a ring for a transkateterny anuloplastika for treatment of patients with a regurgitation of the mitralny valve. The headquarters of the company is located in Santa-Rose, the State of California.

History

2018: Boston Scientific purchased Millipede

On December 27, 2018 Boston Scientific announced the American producer of the medical equipment Millipede Medical purchase. The cost of the transaction is estimated approximately at $325 million with a possibility of payment of additional $125 million at successful product introduction of the sold company for the market.

Ring for the annuloplastiki Iris

Boston Scientific originally invested in development of Millipede $90 million in January, 2018, with a condition of acquisition of the remained stocks of the company in case of success. Completion of the first clinical trial of a system of the annuloplastiki Iris conducted by Millipede company became the basis for the final transaction. The cofounder and the CEO of Millipede Randy Lashinski noted that the company was very pleased with the first results of the program of clinical trials and considers the transaction an excellent opportunity for wider circulation of a new type of products which will help patients with defects of the mitralny valve.

The Iris system uses a complete ring of the annuloplastiki to reduce the size of an expanded mitralny ring of the patient. Iris is developed for the combined use with the system of transseptalny delivery and can be used as the self-contained unit or with other devices intended for patients with a heavy mitralny regurgitation as the representative of Boston Scientific reported.

According to developers, the Iris system can become extremely necessary option of treatment of a functional mitralny regurgitation at patients with the progressing heart failure. This device is developed so that it could be configured easily under a status and anatomic features of the specific patient.^[1]

Notes